<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03405272</url>
  </required_header>
  <id_info>
    <org_study_id>SCT200mCRCⅡ</org_study_id>
    <nct_id>NCT03405272</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC</brief_title>
  <official_title>Recombinant Anti-EGFR Monoclonal Antibody（SCT200） in Patients With Chemotherapy- Refractory Wild Type RAS and BRAF Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinocelltech Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sinocelltech Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR
      Monoclonal antibody（SCT200）in patients with wild-type RAS and BRAF mCRC treated with
      fluorouracil, oxaliplatin and irinotecan after failure of standard therapy
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 12, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Treated with recombinant anti-EGFR Monoclonal antibody（SCT200）until disease progression</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Single Arm, Open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 year</time_frame>
    <description>The achievement of either a partial response (PR) or complete response (CR), according to RECIST 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate - left side</measure>
    <time_frame>1 year</time_frame>
    <description>The achievement of either a partial response (PR) or complete response (CR), left side mCRC patients treated by SCT200. according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best of response</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients in each response category（CR, PR, SD, PD）, according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the time from the date that the response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>1 year</time_frame>
    <description>The achievement of any a stableresponse（SD）, partial response (PR) or complete response (CR), according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the time from first dose of SCT200 to documentation of a response.according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as time from first dose of SCT200 until first documentation of Progression or death, whichever comes first， according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Defined as the time from first dose of SCT200 until death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>recombinant anti-EGFR monoclonal antibody（SCT200）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Anti-EGFR Monoclonal Antibody（SCT200）</intervention_name>
    <description>Experimental: recombinant anti-EGFR monoclonal antibody（SCT200） Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.</description>
    <arm_group_label>recombinant anti-EGFR monoclonal antibody（SCT200）</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to provide written informed consent and can understand and comply with the
             requirements of the study;

          2. Men and women ≥ 18 years of age;

          3. Life expectancy of longer than 3 months ( clinical assessment);

          4. With an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1;

          5. Have been diagnosed as mCRC verified histologically;

          6. Patients treated with fluorouracil, oxaliplatin and irinotecan after failure of
             standard therapy. Disease progressed or developed non-tolerable toxicity after
             systemic chemotherapy：a. at least one treatment cycle should be completed, and
             maintenance therapy using one of the doublets is considered as the same line of
             therapy ; b. May have received adjuvant therapy for primary colorectal cancer provided
             that at least 6 months have elapsed from the time the adjuvant therapy was concluded
             and recurrent disease was documented;

          7. RAS and BRAF wildtype status of primary colorectal cancer or related metastasis;

          8. Adequate organ and marrow function as defined below:

             Absolute neutrophil count (ANC) greater than/equal to 1.5×l09/L; Platelets greater
             than/equal to 75×109/L; Hemoglobin greater than/equal to 80g/L; Aspartate
             aminotransferase (AST)/alanine aminotransferase (ALT) less than/equal to 2.5 times
             IULN, or less than/equal to 5 times IULN if known liver metastases; Total bilirubin
             less than/equal to 1.5 within institutional upper limit of normal (IULN); Serum
             creatinine less than/equal to 1.5 times IULN; Electrolyte: magnesium greater
             than/equal to normal.

          9. According to RECIST 1.1 , patients must have at least one measurable lesion that can
             be accurately assessed at baseline and is suitable for repeated assessment by CT, MRI.
             Longest diameter greater than/equal to10mm（CT scan slice thickness no greater than 5
             mm）, a lymph node must be ≥15mm in short axis when assessed by CT scan.

        Exclusion Criteria:

          1. Patient with active brain metastasis or indicated for symptomatic treatment for brain
             metastasis, untreated with proper radiation therapy, showing clinical symptoms or
             symptom stable time less than 28 days;

          2. Patients with other primary malignancies within the past 5 years except non-melanoma
             skin cancer, carcinoma in situ of cervix or prostatic intraepithelial neoplasia;

          3. Patients who are allergic to analogue of SCT200 and/or its inactive ingredients;

          4. Patients administrated EGFR target treatment including EGFR TKI agent or anti- EGFR
             monoclonal antibody;

          5. Within 4 weeks, patients received anti-tumor drugs (such as chemotherapy, hormone
             therapy, immune therapy, the antibody therapy, radiotherapy) or research drugs, or
             patients with grade 2 or more adverse reaction caused by previous anti-tumor
             therapy(except alopecia or neurotoxicity grade 2 or less);

          6. Patients are currently enrolled in other research devices or in research drugs, or
             less than 4 weeks from other research drugs or devices.

          7. Patients received major surgery(such as need general anesthesia ) within 4 weeks ,
             should recover from the injury associated with the surgery.

          8. Patients treated with EPO, G-CSF or GM-CSF.

          9. Patients who have clinically significant cardiovascular disease (defined as unstable
             angina pectoris, symptomatic congestive heart failure (NYHA, greater than II),
             uncontrollable severe arrhythmia);

         10. Patients occurred myocardial infarction within 6 months.

         11. Patients who have interstitial lung disease, such as interstitial pneumonia, pulmonary
             fibrosis, or CT or MRI reminder ILD .

         12. Patients with clinical symptoms, required clinical intervention or stable time less
             than 4 weeks of serous cavity effusion (such as pleural effusion and ascites);

         13. Patients with serious psychological or psychiatric disorders which may affect subject
             compliance in this clinical study;

         14. Pregnant or lactating women, or women who planned to be pregnant within 6 months of
             treatment;

         15. Patients who were not willing to accept effective contraceptive measures (including
             male or female subjects) during treatment and within 6 months after treatment;

         16. Patients with active hepatitis B or active hepatitis C, etc. (for patients with a
             history of hepatitis B, whether treated or not, HBV DNA ≥104 or ≥ 2000IU/ml, HCV
             RNA≥15IU/ml); HIV antibody positive (if there is no clinical evidence suggesting that
             there may be HIV infection, there is no need to detect);

         17. Patients with uncontrolled active infections before enrollment 2 weeks (except simple
             urinary tract infection or upper respiratory tract infection);

         18. Patients have alcohol or drug addiction;

         19. Inability to comply with study and/or follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yuankai shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xiaoling yang</last_name>
    <phone>0086-10-58628288</phone>
    <phone_ext>9492</phone_ext>
    <email>xiaoling_yang@sinocelltech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>kangsheng gu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer hospital Chinese academy of medical sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>yuankai shi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>guanghai dai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>jianfeng zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>yigui chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital Of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>yanhong deng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>yuxian bai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital.</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>suxia luo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>xianli yin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>peiguo cao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>lingjun zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>ying cheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>wei li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>yajie gao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiking Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>yongzhan nie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lin Yi Cancer Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>jianhua shi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>tianshu liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>yali shen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>yi ba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>mayinuer aili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>jie'er ying, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Full human anti-EGFR monoclonal antibody (SCT200)</keyword>
  <keyword>metastatic colorectal cancer （mCRC）</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

